CA-PROVEN-SKINCARE
19.7.2022 10:07:07 CEST | Business Wire | Press release
PROVEN , the expert in personalized skincare, today announced its international expansion into the European Union and the United Kingdom. Products are currently available to purchase. This is PROVEN’s first international expansion since it launched in Canada in July 2021. The PROVEN team made the decision to expand across the Atlantic due to the global demand for personalized skincare solutions. This expansion comes after a period of extraordinary growth for the company, which includes the launch of its first new product since 2019, the Eye Cream Duo, and having been granted a groundbreaking patent that protects PROVEN’s use of personalization in skincare.
Since its founding in 2017 and launch in 2019, PROVEN Skincare has grown rapidly to become the leading skincare personalization brand. The company has launched five products personalized to customers’ unique needs, received the 2018 MIT Artificial Intelligence Technology Award, was awarded Best Use of Technology at the 2022 Glossy Beauty Awards for its proprietary Skin Genome Project™, and reached more than $30 million in revenue in just three years.
“I am incredibly proud to bring PROVEN’s personalized, data and AI-backed products to the people of the European Union and the United Kingdom,” said PROVEN co-founder and CEO Ming S. Zhao . “Too many consumers still rely on one-size-fits-all skincare products that do not take into account their unique concerns and needs. PROVEN provides personalized, adaptive, effective skincare solutions that take into account a person's skin, life, and environment. The entire PROVEN team is thrilled to enter these new markets and provide people with skincare solutions as unique as they are.”
In order to provide personalized skincare to customers across the European Union and the United Kingdom, the PROVEN team gathered extensive environmental data about the region and executed a major tech build to incorporate it into PROVEN's existing AI. Integrating local environmental conditions into the skincare formulas is essential for effective skincare products.
PROVEN was founded in 2017 by Ming Zhao and Dr. Amy Yuan and launched in 2019. Ming was in the midst of a career in private equity, working long hours when she began to notice the quality of her skin was suffering. She embarked on a personal mission to find products to solve her problems but found that most were expensive, didn’t work consistently, and the trial and error of trying to find something that worked was time-consuming.
She brought this up with her friend Amy, who just so happened to be a Computational Physicist at Stanford, who was having her own skin challenges. Recognizing that the beauty industry lacked a brand that offered personalized and effective solutions, the two joined forces to create a holistic, personalized approach to skincare that is completely backed by data. The result was PROVEN, which harnesses the power of big data and AI to create personalized skincare products.
PROVEN creates simple, personalized, and clinically proven skincare products at scale thanks to its proprietary Skin Genome Project ™ — the largest beauty database on earth. The Skin Genome Project™ takes the following data into account in order to craft personalized products for consumers:
- The effectiveness of over 20,238 skincare ingredients.
- Information about over 100,000 individual products (luxury, prescription, generic, etc.).
- Over 20 million testimonials from real people.
- Over 4,000 scientific publications.
- The water hardness, humidity level, and UV index where you live.
PROVEN currently offers five products personalized to customers’ unique needs. The products include Personalized Cleaner, Personalized Day Moisturizer, Personalized Night Cream, Personalized Day Eye Cream, and Personalized Night Eye Cream. The products can be conveniently purchased as systems or purchased separately.
PROVEN has only been available in the United States and Canada until this expansion.
About PROVEN
PROVEN is a technology company that harnesses the power of big data and AI to create personalized skincare products. At PROVEN we are building a global self-care movement based on technology and personalization. Through our proprietary Skin Genome Project™ — the largest beauty database on earth — we’ve analyzed over 25 million consumer testimonials and 4,000 skin-related scientific papers to create simple, personalized, and clinically-proven skincare products. PROVEN is a Y Combinator alum and 2018 MIT AI Technology Award recipient. Learn more at www.provenskincare.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005333/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
Canva Announces Anthropic Collaboration to Bring AI-Powered Design to Millions17.4.2026 17:51:00 CEST | Press release
New collaboration brings Canva into Claude Design by Anthropic, turning AI-generated ideas into fully editable, on-brand designs Canva, the world’s leading all-in-one visual communication platform, today announced the next chapter in its two-year strategic collaboration with Anthropic, bringing Canva directly into the newly launched Claude Design by Anthropic Labs, one day after unveiling Canva AI 2.0 to a crowd of 6,500 people at Canva Create in Los Angeles.. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260410843169/en/ Canva and Claude Canva is also today introducing HTML importing, a new capability that makes it easy to bring interactive content generated in tools like Claude into the Canva editor for drag-and-drop collaboration, refinement, and publishing. The collaboration makes it easier for Claude Design users to turn AI-generated drafts and ideas into fully editable designs in Canva, where they become collaborative
Andersen Consulting tilføjer samarbejdsfirmaet Nuvolar17.4.2026 15:43:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform for digitale transformation gennem en samarbejdsaftale med Nuvolar, et teknologikonsulenthus med speciale i cloudbaseret softwareudvikling og avancerede Salesforce-implementeringer. Nuvolar, der blev stiftet i 2008 og har hovedsæde i Spanien, leverer end-to-end digital produktudvikling med dyb ekspertise inden for Salesforce, specialudviklede web- og mobilapplikationer, full-stack udvikling, UX/UI-design, produktledelse og langsigtede supporttjenester. Med mere end 110 fagfolk fordelt over Barcelona, Madrid, Miami og Mexico City arbejder virksomheden med kunder inden for luftfart, sundhedsvæsen, forbrugsgoder, medicinalindustrien samt hotel- og restaurationsbranchen for at designe og implementere skalerbare, forretningskritiske platforme, der optimerer driften og fremskynder den digitale transformation. "Samarbejdet med Andersen Consulting giver os mulighed for at levere vores ekspertise i en større skala," udtalte Marc Vivas, administrerende di
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom